

Serial No. 08/484,542

Remarks


Claims 56 and 57 have been amended in this supplemental amendment. Claims 27-35 and 56-60 are active in this application.

Support for the amendment of claim 56 is found in the specification at page 8, line 19. Support for the amendment of claim 57 is found in the specification at page 10, lines 5-7. No new matter has been added.

Provided herewith is a version of amended claims 56 and 57, with markings to show the changes made.

In the amendment and reply filed October 9, 2001, claims 29, 31 and 33 were amended. In the version of the amended claims with markings to show changes made that was filed with the amendment, amended claim 29 was inadvertently numbered incorrectly as claim 30, and amended claim 33 was inadvertently numbered incorrectly as claim 34. Accordingly, provided herewith is a version of correctly numbered amended claims 29, 31 and 33, with markings to show changes made.

Respectfully submitted,

  
Grant E. Reed  
Attorney for Applicant  
Registration No. 41,264  
Phone: 317-276-1664

Eli Lilly and Company  
Patent Division/DC 1501  
Lilly Corporate Center  
Indianapolis, Indiana 46285


**BEST AVAILABLE COPY**12/11/01

## CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

KELLY L. RAMSEY

Type or print name of person signing certification

  
Signature

12/11/01  
Date

Serial No. 08/484,542

**Version Of Amended Claims 56 and 57, With Markings  
To Show Changes Made**

56. (Once Amended) The composition of Claim 35, wherein the phenolic compound [preservative] is selected from the group consisting of phenol and m-cresol.

57. (Once amended) The composition of claim 28, wherein the composition is a pharmaceutical composition that further comprises a phenolic compound, glycerol, and a pharmaceutically acceptable buffer.

**BEST AVAILABLE COPY**

Serial No. 08/484,542

**V rsion Of Amended Claims 29, 31 and 33 (Amended October 9,  
2001), With Markings To Show Changes Made**

29. (Once Amended) The composition of Claim 28, wherein the solution comprises [further comprising from] about 0.2 mole to about 0.7 mole of zinc per mole of fatty acid-acylated insulin.

31. (Once Amended) The composition of Claim 30, further comprising a phenolic compound at a concentration of from 0.5 mg to 5 mg [of] per milliliter of the aqueous solution.

33. (Once Amended) The composition of claim 32, wherein the fatty acid-acylated insulin is N-palmitoyl LysB29 human insulin, and wherein the solution comprises [is comprised of] from about 0.3 mole to about 0.55 mg per milliliter of the aqueous solution.

**BEST AVAILABLE COPY**

Fax

FAX RECEIVED

OFFICIAL

DEC 12 2001

GROUP 1600

12  
*Lilly*  
Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285  
U.S.A.

Legal Department - Patent Division

**To: Marianne P. Allen, Primary Examiner**

Company: USPTO  
Fax: 1-703-305-3014  
Phone: 1-703-308-0666  
Date: December 11, 2001

From: Grant E. Reed  
Fax: 317-276-5172  
Phone: 317-276-1664  
Total Pages: 5

Re:           Applicant: Mark Brader, et al.  
              Serial No.: 08/484,542  
              Filed: June 7, 1995  
              For: Stabilized, Acylated Insulin Formulations  
              Our Docket No.: X-10097

**Privileged and Confidential Communication****BEST AVAILABLE COPY**

If there are any transmittal problems please call: (317) 651-2733.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.